These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1558393)

  • 1. [Pharmacokinetics and action mechanism of anthracyclines].
    Fukushima T; Ueda T; Nakamura T
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):445-50. PubMed ID: 1558393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
    Tapiero H; Nguyen-Ba G; Lampidis TJ
    Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can cytotoxic activity of anthracyclines be related to DNA damage?
    Nishiyama M; Horichi N; Mazouzi Z; Bungo M; Saijo N; Tapiero H
    Anticancer Drug Des; 1990 Feb; 5(1):135-9. PubMed ID: 2317255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
    Tsuruo T; Oh-Hara T; Sudo Y; Naito M
    Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of aclarubicin and its metabolites in humans and their disposition in blood cells.
    Ando S; Nakamura T; Kagawa D; Ueda T; Nishimura T; Kubo A; Tsutani H; Sasada M; Uchino H
    Cancer Treat Rep; 1986 Jul; 70(7):835-41. PubMed ID: 3459574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death.
    Gieseler F; Nüssler V; Brieden T; Kunze J; Valsamas S
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):25-8. PubMed ID: 9476145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
    Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
    Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
    Umezawa K; Kunimoto S; Takeuchi T
    Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
    Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
    Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells.
    Fukushima T; Ueda T; Uchida M; Nakamura T
    Int J Hematol; 1993 Apr; 57(2):121-30. PubMed ID: 8494991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
    Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
    J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
    Nagata T; Higashigawa M; Shimono Y; Cao DC; Yan Mao X; M'soka T; Inamochi H; Hori H; Kawasaki H; Sakurai M
    J Exp Clin Cancer Res; 1998 Dec; 17(4):435-42. PubMed ID: 10089064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.
    Capranico G; Soranzo C; Zunino F
    Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
    Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity.
    Faderl S; Estrov Z; Kantarjian HM; Harris D; Van Q; Fokt I; Przewloka T; Godlewski C; Woynarowski JM; Priebe W
    Anticancer Res; 2001; 21(6A):3777-84. PubMed ID: 11911247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
    Burres NS; Myers MT; Sartorelli AC
    Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.